NTRK3 fusion

Infantile fibrosarcoma, ETV6::NTRK3 gene fusion. (@RZitwer)

🔥E-learning from @DrEzraCohen on TRK fusion-positive thyroid cancers. KEY POINTS ✅#NTRK fusions = more common in paediatric vs adult #thyroid cancer ✅#NTRK2 fusions not seen ✅Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/NMMjp4HiJc #MedEd (@PresOnc_Connect)

Interesting learning from @DrEzraCohen on #TRK fusion-positive thyroid cancers ✅#NTRK fusions more common in paediatric vs adult #thyroidcancer ✅#NTRK2 fusions not seen ✅Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/6NePVisJwk #MedEd (@PresOnc_Connect)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @OncoAlert https://t.co/3YSK5ytxdR (@VivekSubbiah)

New learning from @DrEzraCohen on #TRK fusion-positive thyroid cancers. KEY POINTS -#NTRK fusions = more common in paediatric vs adult #thyroid cancer -#NTRK2 fusions not seen -Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/W3nDR66sYB #MedEd (@ntrkconnectinfo)

New learning from @DrEzraCohen on TRK fusion-positive thyroid cancers. KEY POINTS -#NTRK fusions = more common in paediatric vs adult #thyroid cancer -#NTRK2 fusions not seen -Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/BctFnKUlAS #MedEd (@ntrkconnectinfo)

⭐️Novel mechanism to RET inhibitor resistance -->🎯 NTRK fusion !👉 Validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🫁 #LCSM #NSCLC #precisionmedicine @Annals_Oncology @OncoAlert @myESMO https://t.co/ppL7gIuCP4 (@VivekSubbiah)

A rare case of ETV6/NTRK3 fusion in an adult myxofibrosarcoma. Hard to detect easy to treat! #sarcoma #NTRKs @amanda_psyrri https://t.co/MKfEBcBsr8 (@AKyriazoglou)

Selpercatinib apprvd for RET fusion+ solid tumors 63% pts w/ clinical benefit, 2 CR and 16 PR, n=41 🔜 @OncoKB 5th tumor-agnostic @US_FDA approval (MSI-H [2017], NTRK1/2/3 fusions [2018], TMB-H [2020], BRAF V600E [2022]) https://t.co/OuLRus2uXe 👏@VivekSubbiah, @alexdrilon👏 (@CDebyaniPhD)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/KLJYk0qmep (@VivekSubbiah)

⭐️Novel mechanism to RET inhibitor resistance👉🎯 NTRK fusion !👉Validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🫁 #LCSM #NSCLC #precisionmedicine @Annals_Oncology @OncoAlert @myESMO https://t.co/cFJa5k9Rj6 (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer https://t.co/I1oI8BQ9OB (@VivekSubbiah)

⭐️Novel mechanism to RET inhibitor resistance -->🎯 NTRK fusion !👉 Validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🫁 #LCSM #NSCLC #precisionmedicine @Annals_Oncology @OncoAlert @myESMO https://t.co/I1oI8BQ9OB (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @Annals_Oncology https://t.co/fuF4mbJvcC (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer - Annals of Oncology https://t.co/xHo1Eb4Eyr (@VivekSubbiah)

12-month child with unresectable leg #infantile #fibrosarcoma with ETV6- NTRK3 fusion, post 2 mths of #larotrectinib, #Partial Response @NTRKers @ntrkconnectinfo @RashiKapoor17 @DrManasKalra1 @VivekSubbiah #precision #oncology #sarcoma #limb #salvage (@samdoc_mamc)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @myESMO https://t.co/mTP10Mog8B (@VivekSubbiah)

⭐️Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer #PrecisionMedicine @Annals_Oncology @OncoAlert https://t.co/SLD6CeCMVs (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer #ret #PrecisionMedicine https://t.co/yPtoNabV6w (@VivekSubbiah)

Is this exclusive to RET fusions? We show here that sarcoma cells with another fusion, NTRK3 (yes, we established NTRK3 fusion sarcoma models too!), display a similar adaptation, expanding the applicability of our work. (17/19) (@Odintsov_I)

9 d. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/qjJmfYrdxh (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer https://t.co/wZqoGuUmFk (@VivekSubbiah)

4/4 💥Now 👉Patient-driven discovery + post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🧬🎯💥 Larotrectinib+ Selpercatinib in NTRK + RET fusion 🫁 @Annals_Oncology https://t.co/vITKsvBjw7 (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer 🫁 @Annals_Oncology https://t.co/f0XoxZpxZf (@VivekSubbiah)

Off target RET resistance 👉NTRK3 fusion 👉 NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/eGpRCWA3Br (@VivekSubbiah)

In our small validation with the Idylla Cartridge NTRK3 fusions are not well detected, specially in Thyroid Papillary Cancer were high levels of basal NTRK expresión can give a false negative result. Intreagued by this false +, ok in Met exon 14, ret fusión, Ros1 and Alk fusion (@GRecondoMD)

"Update: No NTRK3 fusion detected by RNA NGS (Archer FusionPlex Sarcoma panel)" (@Tony_Calles)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/ja6ExtEXWM (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer - Annals of Oncology https://t.co/y0Lnf7MCu9 (@weldeiry)

⭐️Novel mechanism to RET inhibitor resistance -->🎯 NTRK fusion !👉 Validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🫁 #LCSM #NSCLC #precisionmedicine @Annals_Oncology @OncoAlert @myESMO https://t.co/ppL7gIu4Zw (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer - Annals of Oncology https://t.co/PKuEfV8UEO (@Dr_R_Kurzrock)

We recently reported NTRK3 fusion as mechanism of resistance in a patient with RET fusion lung cancer 👇🏼 (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer ⁦@Annals_Oncology⁩ https://t.co/fH6x3woQJn (@VivekSubbiah)

🎯Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @OncoAlert https://t.co/fH6x3woQJn (@VivekSubbiah)

⭐️Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/xDgtCbRJoy (@VivekSubbiah)

⭐️Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/6T35Nj9dpp (@VivekSubbiah)

+ NTRK fusion as mechanism of resistance to RET inhibitor👉🏼Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/yeuQIWJI3q (@VivekSubbiah)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer https://t.co/yeuQIWJI3q (@VivekSubbiah)

5/5 Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology https://t.co/yeuQIWJI3q (@VivekSubbiah)

3/5 ⭐️🚨Now showing NTRK fusion as mechanism of RET fusion resistance ! 👉Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer https://t.co/7udm02jlkX (@VivekSubbiah)

5/5 We report 👉KHDRBS1-NTRK3 fusion as mechanism of acquired resistance to Selpercatinib in KIF5B- RET fusion + NSCLC @Annals_Oncology @OncoAlert @myESMO #LSCM ://www.annalsofoncology.org/article/S0923-7534(21)00127-7/fulltext#back-bib4 (@VivekSubbiah)

🥁🥁🥁JUST IN👉Novel mechanism of RET resistance --> NTRK fusion !👉 Validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer #LCSM #NSCLC @Annals_Oncology @OncoAlert @myESMO https://t.co/vKvGpIyoX0 (@VivekSubbiah)